## Supplementary Table 2. Mean PANSS Total Score Change From Baseline by Lead-in Study Treatmenta and Study Visit (Observed Cases)

|  | Placebo‒OLZ/SAM | OLZ/SAM‒OLZ/SAM | Olanzapine‒OLZ/SAM | All Patients |
| --- | --- | --- | --- | --- |
| Baseline, n | 74 | 90 | 84 | 248 |
| Mean (SD) | 84.6 (20.5) | 76.5 (12.5) | 76.4 (15.2) | 78.9 (16.5) |
| Week 4, n | 74 | 90 | 84 | 248 |
| Change from baseline, mean (95% CI) | −9.5  (−13.1, −5.8) | −5.5  (−7.3, −3.6) | −5.0  (−7.0, −3.0) | −6.5  (−7.9, −5.0) |
| Week 8, n | 70 | 83 | 79 | 232 |
| Change from baseline, mean (95% CI) | −14.9  (−19.0, −10.8) | −8.1  (−10.3, −5.9) | −7.6  (−9.7, −5.5) | −10.0  (−11.7, −8.3) |
| Week 12, n | 67 | 80 | 78 | 225 |
| Change from baseline, mean (95% CI) | −16.3  (−20.6, −11.9) | −9.6  (−12.3, −6.9) | −8.7  (−11.3, −6.2) | −11.3  (−13.1, −9.4) |
| Week 24, n | 62 | 74 | 74 | 210 |
| Change from baseline, mean (95% CI) | −18.0  (−22.7, −13.2) | −10.8  (−14.4, −7.3) | −9.8  (−13.1, −6.4) | −12.6  (−14.8, −10.3) |
| Week 36, n | 57 | 68 | 68 | 193 |
| Change from baseline, mean (95% CI) | −19.4  (−24.0, −14.9) | −14.0  (−16.9, −11.1) | −11.0  (−14.3, −7.8) | −14.6  (−16.6, −12.5) |
| Week 52, n | 56 | 63 | 64 | 183 |
| Change from baseline, mean (95% CI) | −21.1  (−26.4, −15.7) | −15.6  (−18.6, −12.6) | −12.7  (−15.9, −9.5) | −16.2  (−18.5, −14.0) |

OLZ/SAM, combination of olanzapine and samidorphan; PANSS, Positive and Negative Syndrome Scale.

aTreatment received during ENLIGHTEN-1 followed by OLZ/SAM in this study.